Cimzia Articles
US gastroenterologists increasingly using biologics to treat Crohn's patients in remission
6 March 2013
UCB heading for growth phase as new products drive 2012 sales
28 February 2013
UCB files for US and EU approval for Cimzia for psoriatic arthritis and axial spondyloarthritis
20 February 2013
UCB links with Astellas for Cimzia in Japan
2 February 2012
Otsuka Pharma and UCB re-focus collaboration
16 January 2012
Belgium’s UCB updates on Cimzia and epratuzumab trials
11 November 2010
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
Rheumatoid arthritis patient share of Actemra projected to exceed that of Cimzia and Simponi among US Medicare population
4 November 2010
XOMA sells royalty rights on Cimzia for $4 million
20 August 2010
Abbott/Eisai’s Humira most favored among biologics for Crohn's disease and ulcerative colitis, says DR report
9 April 2010
Belgium’s UCB posts disappointing 2009 results, but projects better future based on newer drugs
3 March 2010
Despite minimal uptake in Crohn's market, Stelara's premium price will result in nearly $337 million sales in 2018 and briakinumab $130 million
23 February 2010
Belgium’s UCB to maximize US focus and resources on core products, hiving off primary care to Sanofi and Teva
1 February 2010
UK’s NICE does about turn on UCB’s Cimzia, backing it use for RA, but with cost-sharing deal
21 January 2010
Bristol-Myers Squibb gains rights to Alder’s rheumatoid arthritis biologic for up to $1 billion
11 November 2009
UCB’s Cimzia approved for RA in Europe
7 October 2009
Health Canada working to update labeling of TNF blockers
29 August 2009
US FDA says cancer warnings required for TNF blockers
5 August 2009
Cimzia benefits hard-to-treat CD patients
3 June 2009
Stock Commentary - Europe - week to May 18, 2009
21 May 2009
UCB teams with OXO to ease RA drug
18 May 2009
UCB gets FDA appro for Cimzia in RA
15 May 2009
Strong interest in J&J's Simponi
13 May 2009
UCB absorbs Zyrtec patent expiry, but 2008 profit still down 74% on restructuring charges
9 March 2009
UCB targets FDA Cimzia RA response in 2nd qtr
16 February 2009
Stock Commentary - Europe - week to Feb 9, 2009
16 February 2009
Cimzia plus MTX inhibits RA joint damage
1 December 2008
UCB presents data from two Ph III Cimzia trials
3 November 2008
UCB's Cimzia improves Crohn's lesions
13 October 2008
US FDA calls for tougher warnings on TNF-alpha drugs on 240 cases of histoplasmosis
15 September 2008
UCB to cut 17% of staff in major restructuring
8 September 2008
US FDA set for even fewer approvals in 2008
1 September 2008
UCB's Cimzia under review for active RA
7 July 2008
UCB report is cagey about interim results
26 May 2008
UCB
28 April 2008
UCB drops 12% on Neupro batches recall
31 March 2008
UCB's Cimzia effective in treatment refractory CD
10 March 2008
UCB raises guidance for 2008 above consensus
24 December 2007
CHMP issues negative view on Cimzia in Crohn's
26 November 2007
Cimzia plus MTX inhibits joint damage in RA
19 November 2007
Cimzia maintains remission in CD for up to 18 months
5 November 2007
Strong Ph III data on UCB's Cimzia in NEJM
23 July 2007
Stock Commentary - Europe - week to July 16, 2007
23 July 2007
UCB's Cimzia shows efficacy at 80 weeks
28 May 2007
Cimzia key drug in UCB 2007 R&D update
7 May 2007
Stock Commentary - Europe - week to April 9
16 April 2007
Stock Commentary - Europe - week to March 26
2 April 2007
Delay likely for UCB's Cimzia in Crohn's
2 April 2007
UCB's Cimzia performs well in psoriasis trial
12 February 2007
Anti-TNF drug sales to hit $1.3B by 2015
22 December 2006
Cimzia of benefit in CD regardless of prior infliximab use
13 November 2006
Cimzia performs well in Ph II psoriasis study
16 October 2006
UCB awards Chair in IBS management
25 September 2006
Devgen sees good data in trials of oral TNF inhibitors
28 August 2006
UCB 1st-half results ahead of forecasts
7 August 2006
Stock Commentary - Europe - week to July 24, 2006
24 July 2006
Strong Ph III data for UCB's Cimzia
29 May 2006
UCB submits Cimzia MAA to EMEA
15 May 2006
UCB sees 2005 income grow to 270M euros
20 March 2006
UCB projects income of 260 M euros for 2005
19 December 2005
Stock Commentary - Europe
8 August 2005
UCB 1st-half net profits leap 232%
8 August 2005
UCB's Ph III Cimzia trials meet endpoint
1 August 2005
Showing 1-81 of 81 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
